EUVIMEDEUVIMED entdecken
Leserbrief

Ferritin, C‐Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH

Steven Rowe iD, Mariam Goubran iD, Mateo Sarmiento Bustamante iD, Saishravan Shyamsundar iD, Bridget Austin, Kathleen McNicholas, Marley Blommers, Junyan Shi iD, Lisa K Peterson iD, Lusia Sepiashvili, Andre Mattman, Joshua D Brandstadter iD und 2 weitere

American Journal of Hematology · 2025

DOI: 10.1002/ajh.70081 ↗

Kurz gefasst

Leserbrief in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Steven Rowe und 13 weiteren Autor:innen. Beteiligte Einrichtung: Discipline of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada. Hauptthemen laut MEDLINE: C-Reactive Protein, Ferritins, Interleukin-2 Receptor alpha Subunit, Lymphohistiocytosis, Hemophagocytic. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 12 Literaturangaben. Gefördert von: United States Food and Drug Administration, NHLBI NIH HHS, Castleman Disease Collaborative Network.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

C-Reactive ProteinFerritinsInterleukin-2 Receptor alpha SubunitLymphohistiocytosis, HemophagocyticCytokine Release SyndromeHumansDiagnosis, DifferentialMaleFemaleBiomarkersMiddle Aged

Stichwörter der Autor:innen

CRPCastleman diseaseTAFROferritinhemophagocytic lymphohistiocytosissoluble CD25

Substanzen

C-Reactive ProteinFerritinsInterleukin-2 Receptor alpha SubunitIL2RA protein, humanBiomarkers

Autor:innen und Institutionen

  • Discipline of Medicine, Memorial University of Newfoundland, St. John's, Newfoundland, Canada.
  • Division of Hematology, University of British Columbia, Vancouver, British Columbia, Canada.
  • Center for Cytokine Storm Treatment & Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Faculty of Medicine, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Department of Pathology and Laboratory Medicine, Vancouver General Hospital and University of British Columbia, Vancouver, British Columbia, Canada.
  • Department of Pathology, University of Utah, Salt Lake City, Utah, ARUP Institute for Clinical and Experimental Pathology, Salt Lake City, Utah, USA.

ORCID-Profile: Steven Rowe, Mariam Goubran, Mateo Sarmiento Bustamante, Saishravan Shyamsundar, Junyan Shi, Lisa K Peterson, Joshua D Brandstadter, David C Fajgenbaum, Luke Y C Chen

Förderung

  • United States Food and Drug Administration
  • NHLBI NIH HHS
  • Castleman Disease Collaborative Network
  • FDA HHS
  • Hsu & Taylor Family through the VGH & UBC Hospital Foundation and the Nova Scotia Health Innovation Hub
  • Recordati Rare Diseases
  • The Colton Center for Autoimmunity at the University of Pennsylvania
  • National Heart, Lung, and Blood Institute

Zitieren

APA

Rowe, S., Goubran, M., Sarmiento Bustamante, M., Shyamsundar, S., Austin, B., McNicholas, K., Blommers, M., Shi, J., Peterson, L. K., Sepiashvili, L., Mattman, A., Brandstadter, J. D., Fajgenbaum, D. C., & Chen, L. Y. C. (2025). Ferritin, C‐Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH. American Journal of Hematology. https://doi.org/10.1002/ajh.70081

Vancouver

Rowe S, Goubran M, Sarmiento Bustamante M, Shyamsundar S, Austin B, McNicholas K, et al. Ferritin, C‐Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH. American Journal of Hematology. 2025. doi:10.1002/ajh.70081

BibTeX
@article{Rowe2025,
  author = {Rowe, Steven and Goubran, Mariam and Sarmiento Bustamante, Mateo and Shyamsundar, Saishravan and Austin, Bridget and McNicholas, Kathleen and Blommers, Marley and Shi, Junyan and Peterson, Lisa K and Sepiashvili, Lusia and Mattman, Andre and Brandstadter, Joshua D and Fajgenbaum, David C and Chen, Luke Y C},
  title = {Ferritin, C‐Reactive Protein, and Soluble CD25 Distinguish TAFRO From HLH},
  journal = {American Journal of Hematology},
  year = {2025},
  doi = {10.1002/ajh.70081}
}
Kostenlos starten →